Design of Experiments (DoE)‐Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose‐to‐Brain Delivery

Naveed Ahmad, Shunping Han, Rifka Nurul Utami, Rafal Baker, Dina O. Helal, Zhuoni Li, Mark D. Tricklebank, Yannis Paloyelis, Julie Wang, Marija M. Petrinovic, Sukhvinder S. Bansal, Khuloud T. Al‐JamalSmall 2025 · DOI

TL;DR

This study presents a novel approach to deliver oxytocin (OT) directly to the brain for treating conditions like autism spectrum disorder (ASD). By optimizing PLGA-based nanoparticles (OT-NP-PEG) using Design of Experiments (DoE), researchers achieved enhanced nose-to-brain delivery, leading to increased brain uptake and a significant increase in self-grooming behavior in mice, indicating maintained bioactivity.

What Problem Does This Paper Address?

Oxytocin (OT) shows promise for regulating social behavior, particularly in autism spectrum disorder (ASD). However, its effectiveness is hampered by the lack of efficient delivery systems that can selectively target the brain while minimizing peripheral side effects. Traditional intranasal (IN) administration of OT often results in inconsistent efficacy due to poor brain penetration. This paper addresses the critical need for an improved delivery platform that can overcome the blood-brain barrier and deliver OT effectively to the central nervous system.

Methods

The researchers employed a Design of Experiments (DoE) approach, specifically a 3³ factorial design, to optimize the formulation of polymeric nanoparticles. This statistical method allowed them to efficiently evaluate the effects and interactions of three key formulation parameters: PLGA concentration, lecithin concentration, and Tween 80 concentration, on nanoparticle size (PS), polydispersity index (PDI), and drug loading (DL%).

For brain targeting, poly(lactic-co-glycolic acid) (PLGA) nanoparticles (OT-NP) were developed. To further enhance nasal mucosal diffusion, a PEGylated version (OT-NP-PEG) was created. To track the delivery and distribution of OT in vivo, [¹⁴C]-radiolabeled OT was synthesized using solid-phase peptide synthesis (SPPS).

Key characterization techniques included:

  • Dynamic Light Scattering (DLS) and Nanoparticle Tracking Analysis (NTA) for particle size and distribution.
  • Zeta potential measurements to assess surface charge.
  • RP-HPLC for drug loading and release studies.
  • Transmission Electron Microscopy (TEM) for visualizing nanoparticle morphology.
  • Liquid Scintillation Counting (LSC) for quantifying radiolabeled OT in biological samples.
  • In vitro cytotoxicity assays (MTT) to evaluate nanoparticle safety.
  • Transwell inserts to assess diffusion through simulated nasal mucus.
  • Behavioral studies (self-grooming frequency) in mice to assess bioactivity.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • DoE as a powerful optimization tool: The study highlights the efficacy of DoE in systematically optimizing nanoparticle formulations, leading to a well-defined set of parameters for achieving desired physicochemical properties.
  • PEGylation enhances nasal diffusion: The addition of PEG to the PLGA nanoparticles (OT-NP-PEG) significantly improved their diffusion through simulated nasal mucus, suggesting better penetration into the nasal cavity.
  • Nose-to-brain (NTB) pathway is effective: The radiolabeled studies clearly demonstrated that intranasal administration of OT-NP-PEG leads to significantly higher brain uptake, particularly in the olfactory bulb and frontal cortex, compared to free OT.
  • Reduced peripheral exposure: The nanoparticle formulation resulted in lower blood and liver exposure of OT, indicating a more targeted delivery and reduced systemic side effects.
  • Behavioral evidence of bioactivity: The observed increase in self-grooming frequency in mice treated with OT-NP-PEG provides crucial behavioral evidence that the delivered OT is biologically active and can engage central OT receptors.
  • [¹⁴C] radiolabeling is key for precise tracking: The use of [¹⁴C]-labeled OT was instrumental in accurately quantifying brain uptake and peripheral distribution, addressing a critical gap in previous studies.

Key Results

  • Optimized Nanoparticles: DoE yielded OT-NP-PEG with a hydrodynamic diameter of ~93-116 nm, a polydispersity index of ~0.20, and zeta potential of -21 to -33 mV.
  • Drug Loading: Drug loading was optimized to ~2.8-3.5% (w/w).
  • Sustained Release: OT-NP-PEG showed sustained release, with >42% and 58% of OT released at 24 and 72 hours, respectively.
  • Brain Uptake: Following IN administration, [¹⁴C] OT-NP-PEG showed significantly higher brain uptake (e.g., 4.00 ± 0.52% ID/g in the olfactory bulb at 10 min) compared to free [¹⁴C] OT (0.37 ± 0.03% ID/g).
  • Reduced Systemic Exposure: [¹⁴C] OT-NP-PEG exhibited lower accumulation in the liver compared to free [¹⁴C] OT.
  • Behavioral Effect: IN administration of OT-NP-PEG (0.7 mg kg⁻¹ OT) significantly increased self-grooming frequency in mice by approximately 2-fold compared to blank NPs.
  • Cytotoxicity: OT-NP formulations showed no significant reduction in cell viability, indicating good biocompatibility.

Limitations and Future Work

  • Pharmacokinetic analysis: While the study demonstrated enhanced brain uptake, future pharmacokinetic studies using LC-MS are recommended to accurately detect both the parent OT and its metabolites in brain tissues, as LSC only detects the carbon-14 label.
  • Behavioral studies in disease models: The current behavioral study was a preliminary proof-of-concept in wild-type mice. Future work should involve evaluating the therapeutic efficacy of OT-NP-PEG in relevant disease models (e.g., ASD models) to determine optimal dosing parameters and confirm therapeutic benefits.
  • Long-term stability and efficacy: Further studies could investigate the long-term stability of the nanoparticles in vivo and their sustained therapeutic effects over extended periods.

Summary updated

Abstract

Oxytocin (OT) is a promising candidate for regulating social behavior in autism spectrum disorder (ASD). However, its inconsistent efficacy can be attributed to the lack of an efficient delivery system that selectively target the brain without inducing peripheral side effects following intranasal (IN) administration. In this study, OT is encapsulated within an FDA-approved poly (lactic-co-glycolic acid) (PLGA) nanoparticles (OT-NP) to improve nose-to-brain (NTB) delivery. A PEGylated version (OT-NP-PEG) is developed to improve nasal mucosal diffusion. Optimization using a design of experiments (DoE) approach produced nanoparticles with hydrodynamic diameters of ≈93-116 nm, polydispersity index ≈0.20, zeta potential -21 to -33 mV, and drug loading ≈2.8-3.5% (w/w). The stable OT-NP-PEG showed sustained release (>42% and 58% at 24 and 72 h) and greater diffusion through simulated nasal mucus. [<sup>14</sup>C] OT is synthesized with chemical and radiochemical yields of 74% and 53%, respectively. Following IN administration in mice, [<sup>14</sup>C] OT-NP-PEG demonstrated rapid brain uptake, particularly in the olfactory bulb and frontal cortex, with reduced blood and liver exposure compared with free [<sup>14</sup>C] OT. Finally, IN OT-NP-PEG significantly increased self-grooming frequency in mice, indicating maintained bioactivity and behavioral effects. Overall, OT-NP-PEG offers a rationally designed nanoplatform for brain-targeted OT delivery in ASD and other neuropsychiatric disorders.
BibTeX
@inproceedings{ahmad2025design,
  author = {Naveed Ahmad and Shunping Han and Rifka Nurul Utami and Rafal Baker and Dina O. Helal and Zhuoni Li and Mark D. Tricklebank and Yannis Paloyelis and Julie Wang and Marija M. Petrinovic and Sukhvinder S. Bansal and Khuloud T. Al‐Jamal},
  title = {{Design of Experiments (DoE)‐Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose‐to‐Brain Delivery}},
  booktitle = {Small},
  year = {2025},
  doi = {10.1002/smll.202511603},
}
Figure